Notice of Intent to Award a Sole Source Contract to research a therapuetic efficacy of botulinum metalloendoprotease inhibitors.

The Defense Threat Reduction Agency (DTRA) intends to negotiate and award a sole source contract to New Jersey Medical School-University of Medicine and Dentistry, Department of Pharmacology & Physiology to research a therapeutic efficacy of botulinum metalloendoprotease inhibitors: protection and recovery of neurotransmitter release and neuromuscular function. The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of FAR 6.302-1. Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive proposals. However, all proposals received within fifteen days after date of publication of this synopsis will be considered by the government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. All inquiries must be submitted in writing to the email address, facsimile number, or mailing address stated herein and to the attention of Mr. Keith Boyea, Contract Specialist, Contract Support. Responses to this notice must be received by close of business, July 11, 2008. Responses must include your business name, point of contact, address and telephone number with area code. Telephone requests or inquiries will not be accepted. Requests may be emailed to keith.boyea_contractor@dtra.mil. If no responses are received, an award will be made to New Jersey Medical School-University of Medicine and Dentistry, Department of Pharmacology & Physiology.